| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8653092 | PHARMING | Tetrahydro-pyrido-pyrimidine derivatives |
Feb, 2032
(7 years from now) | |
Joenja is owned by Pharming.
Joenja contains Leniolisib Phosphate.
Joenja has a total of 1 drug patent out of which 0 drug patents have expired.
Joenja was authorised for market use on 24 March, 2023.
Joenja is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Joenja from 25 March, 2027.
The generics of Joenja are possible to be released after 19 February, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-430) | Mar 24, 2030 |
| New Chemical Entity Exclusivity(NCE) | Mar 24, 2028 |
Drugs and Companies using LENIOLISIB PHOSPHATE ingredient
NCE-1 date: 25 March, 2027
Market Authorisation Date: 24 March, 2023
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
JOENJA family patents
